Moderna, Inc. (MRNA)
| Market Cap | 16.50B +4.5% |
| Revenue (ttm) | 1.94B -39.9% |
| Net Income | -2.82B |
| EPS | -7.26 |
| Shares Out | 390.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,329,744 |
| Open | 41.85 |
| Previous Close | 40.11 |
| Day's Range | 41.20 - 44.80 |
| 52-Week Range | 22.28 - 55.20 |
| Beta | 1.34 |
| Analysts | Hold |
| Price Target | 30.80 (-27.07%) |
| Earnings Date | Feb 13, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $30.8, which is a decrease of -27.07% from the latest price.
News
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend
MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.
MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options
Moderna (MRNA) experienced a wild start to 2026, with shares nearly doubling before pulling back 20% from the recent 52-week high. Rick Ducat dives into technical trends to watch and the various suppo...
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms
Moderna Inc. (NASDAQ: MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago.
Moderna Narrows Loss, Reiterates 10% Revenue Growth Target
Moderna said it continues to target 10% revenue growth this year, as the company's fourth-quarter loss narrowed from a year earlier.
Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.
Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.
Moderna beats fourth-quarter revenue estimates
Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U.S.
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS ...
Moderna Stock Sports Technical Support Ahead Of Earnings
Pharma stock Moderna (MRNA) is experiencing a sharp pullback from its Jan. 22, 52-week high of $55.20. Last seen down 3.5% at $39.08, the shares are headed for their third-straight weekly loss.
Why is the FDA refusing Moderna's application for a new mRNA flu vaccine?
The U.S. Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the l...
The FDA's refusal to review Moderna's application to sell a new flu shot is part of a pattern of regulatory U-turns and overruling of FDA staff by Vinay Prasad, head of the agency's vaccine division
The head of the agency's vaccine division, Vinay Prasad, has overruled pushback from career staffers.
FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'
The new shot was not compared to “the best-available standard of care in the United States at the time of the study,” an FDA official told Moderna.
The FDA Refuses To Review Moderna's Flu Vaccine
In this week's edition of InnovationRx, we look at the FDA's refusal to review Moderna's flu vaccine, the healthcare giants on Forbes new Greatest Innovators list, why Garner Health is worth $1.35 bil...
Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says
The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development.
Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine.
The vaccine maker says the Food and Drug Administration has refused to review its application to sell a new seasonal flu vaccine.
Wall Street Breakfast Podcast: Amazon Adds BETA To Cart
Amazon (AMZN) acquires a 5.3% stake in BETA Technologies, sharply boosting BETA's premarket share price. Moderna (MRNA) faces an FDA refusal-to-file for its mRNA-1010 influenza vaccine, citing inadequ...
Moderna shares fall after FDA refuses to review new flu vaccine
Moderna shares opened 14% lower in Frankfurt on Wednesday in low volume after the U.S. Food and Drug Administration refused to review the company's approval application for its influenza vaccine.
The FDA has refused to review Moderna's application to sell a new flu shot, the latest move by the Trump administration against vaccines
The company said the agency wouldn't review its application on the grounds that the study testing the shot wasn't sufficient.
Moderna says US FDA refuses to review its influenza vaccine
Moderna said on Tuesday the U.S. Food and Drug Administration will not review its approval application for its influenza vaccine.
Moderna says FDA refuses to review its application for experimental flu shot
The Food and Drug Administration refused to start a review of Moderna's application for its experimental flu shot, the company said. It's another sign of the Trump administration's influence on tighte...
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type A meeting to understand the path forward mRNA-1010 has been...
The FDA has refused to review Moderna's application to sell a new flu shot, the latest move by the administration against vaccines
The company said the agency wouldn't review its application on the grounds that the study testing the shot wasn't sufficient.
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security Strategic agreement will enable access to Modern...
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX) , expanding its lineup of single-stock leveraged ETFs designed f...
CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery
Moderna CEO Stéphane Bancel discusses positive cancer vaccine trial results and the impact GLP-1 drugs on 'Mornings with Maria.' #foxbiusiness #morningswithmaria